Company: RCUS
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001193125-25-028669
Chunk: 41

Company: Arcus Biosciences, Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 41
---
 license for Japan and certain other territories in Asia (excluding China) the development and commercialization rights to each of our programs that arose over a five-year period, which ended in September 2022. As of December 31, 2022, Taiho has licenses to our adenosine receptor antagonist program (including etrumadenant), anti-PD-1 program (including zimberelimab) and anti-TIGIT program (including domvanalimab and AB308). Other Licenses, Collaborations and R&D Arrangements We in-licensed rights to zimberelimab and anti-CD39 antibodies from WuXi Biologics Ireland Limited, and in-licensed rights to products that include an anti-TIGIT antibody, including domvanalimab, from Abmuno Therapeutics LLC. We also have a clinical collaboration agreement with AstraZeneca plc for the PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 non-small cell lung cancer and an agreement with BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Corporate Information We were incorporated in Delaware on April 30, 2015. Our principal executive offices are located at 3928 Point Eden Way, Hayward, CA 94545, and our telephone number is (510) 694-6200. Our website address is www.arcusbio.com. The information on, or that can be accessed through, our website is not part of this prospectus. We have included our website address as an inactive textual reference only. Arcus Biosciences and the Arcus Biosciences logo are the property of Arcus. Trade names, trademarks and service marks of other companies appearing in this prospectus are the property of their respective holders. The Securities We May Offer We may offer shares of our common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in combination, from time to time under this prospectus, together with the applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at the time of any offering. There is no limit on the aggregate amount of the securities that we may offer pursuant to the registration statement of which this prospectus is a part. We may also offer common stock, preferred stock and/or debt securities upon the exercise of warrants. This prospectus provides you with a general description of the securities